BIONTECH
LIVE

Serial Number

79353523

Owner

BioNTech SE

Attorney

Monica Riva Talley

Filing Date

Dec 28, 2021

Add to watchlist:

No watchlists yet
View on USPTO

BIONTECH Trademark

Serial Number: 79353523 • Registration: 7166547

BIONTECH is a trademark filed by BioNTech SE on December 28, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

BioNTech SE (46 trademarks)

An der Goldgrube 12

Entity Type: 94

Trademark Details

Filing Date

December 28, 2021

Registration Date

September 19, 2023

Published for Opposition

July 4, 2023

Goods & Services

medical and scientific research in the field of treatment of immunological diseases, cancer treatment, and treatment of infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of medical and scientific research in the field of treatment of immunological diseases, cancer treatment, and treatment of infectious diseases; medical and scientific research services by compiling data for clinical trials and drug admission

Medical, hygienic and beauty care; healthcare services; provision of medical information and services; provision of medical information to patients and healthcare professionals concerning pharmaceutical products, vaccines, medical products, medical diseases and disorders and related treatments via the Internet; medical services in the field of gene therapy; medical services in the field of cell therapy; medical and health care services; medical services, namely, providing therapies for treating cancer, infectious diseases and immunological diseases; veterinary services, namely, providing therapies for treating cancer, infectious diseases, and immunological diseases; medical and pharmaceutical consultation; medical diagnostic testing, monitoring and reporting services; genetic testing for medical purposes

Pharmaceutical products for the prevention and treatment of cancer, infectious diseases, and immunological diseases, except vitamin preparations, mineral food supplements, probiotics, omega 3 preparations, dietetic substances and food supplements for medical and non-medical purposes; Vaccines; Chemical reagents used for medical purposes; Biochemical reagents used for purposes for the treatment of cancer, treatment of immunological diseases, and treatment of infectious diseases; Macromolecules, namely, nucleic acid sequences and proteins, used for medical and veterinary purposes; cell based immune therapeutics for treatment of cancer, treatment of immunological diseases, and treatment of infectious diseases; diagnostic preparations for clinical or medical laboratory use

Chemicals for use in pharmaceutical industry; active chemical ingredients for use in manufacture of anti-cancer drugs and vaccines; adjuvants for use in manufacture of vaccines; nucleic acids, proteins and peptides for laboratory use; diagnostic preparations for scientific or research use other than for medical purposes

Medical diagnostic devices for analysis of body fluids and biopsies for diagnosis and monitoring of cancer, infectious diseases, and immunological diseases; medical diagnostic devices for analysis of body fluids and biopsies for patient stratification

Business advisory services in the field of electronic commerce; providing business information in the field of electronic commerce; providing business information, namely, customer information on pharmaceutical and medical products through an on-line computer network; wholesale and retail store services featuring pharmaceutical products, medicinal preparations, and medical supplies

Downloadable mobile applications for enabling healthcare professionals and patients to access information on pharmaceutical, medical and vaccine products and services; downloadable computer software for enabling healthcare professionals and patients to access information on pharmaceutical, medical and vaccine products and services; downloadable e-commerce computer software for enabling users to perform electronic business transactions via a global computer network

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 30, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 12, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 12, 2025 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
Jan 31, 2025 NREP
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Aug 26, 2024 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Jun 17, 2024 CRCV
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 8, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 21, 2023 FICS
FINAL DISPOSITION PROCESSED
Dec 21, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 19, 2023 FICR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 25, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 25, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 25, 2023 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 19, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 19, 2023 R.PR
NOTIFICATION PROCESSED BY IB
Jul 11, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 4, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jul 4, 2023 PUBO
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 21, 2023 OP2R
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 20, 2023 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 14, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 26, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
May 3, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 3, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
May 3, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 3, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 31, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 31, 2023 TROA
REFUSAL PROCESSED BY IB
Feb 15, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 20, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jan 20, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 15, 2022 RFCR
NON-FINAL ACTION WRITTEN
Nov 14, 2022 CNRT
APPLICATION FILING RECEIPT MAILED
Nov 11, 2022 MAFR
ASSIGNED TO EXAMINER
Nov 7, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 7, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Nov 1, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 27, 2022 REPR